Accelerating Patient Access to Investigational Drugs in 2015

by | Mar 9, 2015 | 0 comments

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched. This is termed “expanded access” whereby there is no other product that can diagnose, monitor, or treat the patient’s disease or condition, and the patient is not and cannot be enrolled in a clinical study for various reasons (such as patient inclusion criteria or access to a clinical site).

“Compassionate use” was coined early in the HIV/AIDS epidemic when the FDA authorized unapproved investigational drugs for patients in certain cases. The application process was then complex and time consuming. It could take up to 100 hours for physicians to complete the form. FDA recognizes physicians demanding schedules and is simplifying the process to a shorter form for completion within 45 minutes.

The most recent 2015 drafted process is entitled “Individual Patient Expanded Access Applications: Form FDA 3926,” it includes a simplified application form that, when finalized, will be used for requesting the medications, and is designed to greatly simplify and accelerate the process by which a physician can request that FDA permit the use of an experimental — socalled “investigational” — drug or biological product while it’s still being tested to establish its safety.

The bottom line for patients is that while a clinical trial is in process they can apply to access the drug for their disease.

For more information: index.php/2015/02/a-big-stepto-help-the-patients-most-inneed/#.dpuf

Learn more on this topic

Related Blog Posts

Building Awareness on CMT and Supporting the Patient Community – HNF Announces Support from Pharnext

HNFpharnext recently entered into a partnership with the French biopharmaceutical company, Pharnext, to help raise awareness of Charcot-Marie-Tooth (CMT) disease and support the CMT patient community through several initiatives. Building awareness is key! Pharnext’s support will assist HNF in distributing HNF’s CMT Update quarterly newsletter, enhancing the Global Registry for Inherited Neuropathies (GRIN), setting up activities for CMT September Awareness Month in the US and strengthening the CMT Inspire Community.

In Memoriam

The HNF family has lost two great people this summer: Franklin G. Downing Sr. (father of board member Matthew Downing) and George G. Gatta (father of board member Kathleen Zappola).

Targeting PMP22 in CMT1A Patients with Gene Duplication

In previous collaborative work with a group of investigators including Dr Rolf Renne from the University of Florida, Dr. Alex Murashov from East Carolina University and Dr. Lynn Hudson from the NIH-NINDS, we validated a microRNA known as miR29a as a reagent that corrected the expression level of PMP22 in rodent Schwann cells.

Join the conversation

Leave a Comment


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news